SODIUM BICARBONATE INJECTION USP (sodium bicarbonate injection USP) Dosage And Administration

Medical Information
Canada
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for Canadian Healthcare Professionals. Would you like to proceed?

Sodium Bicarbonate Injection USP is administered by the intravenous route.

In cardiac arrest, a rapid intravenous dose of 200 to 300 mmol (mEq) of bicarbonate, given as a 7.5% or 8.4% solution, is suggested for adults. Caution should be observed in emergencies where very rapid infusion of large quantities of bicarbonate is indicated. Bicarbonate solutions are hypertonic and may produce an undesirable rise in plasma sodium concentration in the process of correcting the metabolic acidosis. In cardiac arrest, however, the risks from acidosis exceed those of hypernatremia.

In infants (up to two years of age), the 4.2% solution is recom­mended for intravenous administration at a dose not to exceed 8 mmol (mEq)/kg/day. Slow administration rates and the 4.2% solution are recommended in neonates, to guard against the possibility of producing hypernatremia, decreasing cerebrospinal fluid pressure and inducing intracranial hemorrhage.

In less urgent forms of metabolic acidosis, Sodium Bicarbonate Injection USP may be added to other intravenous fluids. The amount of bicarbonate to be given to older children over a four to eight hour period is approximately 2 to 5 mmol (mEq)/kg of body weight - depending upon the severity of the acidosis as judged by the lowering of total CO2 content, blood pH and clinical condition of the patient.  Bicarbonate therapy should always be planned in a stepwise fashion since the degree of response from a given dose is not precisely predictable.  Initially an infusion of 2 to 5 mmol (mEq)/kg body weight over a period of 4 to 8 hours will produce a measurable improvement in the abnormal acid base status of the blood.  The next step of therapy is dependent upon the clinical response of the patient.  If severe symptoms have abated, then the frequency of administration and the size of the dose may be reduced.

In general, it is unwise to attempt full correction of a low total CO2 content during the first 24 hours of therapy, since this may be accompanied by an unrecognized alkalosis because of a delay in the readjustment of ventilation to normal. Owing to this lag, the achievement of total CO2 content of about 20 mmol (mEq)/liter at the end of the first day of therapy will usually be associated with a normal blood pH.  Further modifi­cation of the acidosis to completely normal values usually occurs in the presence of normal kidney function when and if the cause of the acidosis can be controlled. Values for total CO2, which are brought to normal or above normal within the first day of therapy, are very likely to be associated with grossly alkaline values for blood pH, with ensuing undesired side effects.